This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

**Active Ingredient:** Trospium chloride

**Dosage Form; Route:** Extended release capsule; oral

**Recommended Studies:** Two studies

1. **Type of study:** Fasting  
   **Design:** Single-dose, two-way crossover in-vivo  
   **Strength:** 60 mg  
   **Subjects:** Healthy males and non-pregnant, non-lactating females, general population.

   Additional Comments: Applicants may consider using a reference-scaled average bioequivalence approach for trospium. If using this approach, please provide evidence from your bioequivalence study of high variability in the bioequivalence parameters of AUC and/or Cmax (i.e., within-subject variability ≥ 30%). Please refer to the Bioequivalence Recommendations for Specific Product Guidance on Progesterone Capsules for additional information regarding this approach.

2. **Type of study:** Fed  
   **Design:** Single-dose, two-way crossover in-vivo  
   **Strength:** 60 mg  
   **Subjects:** Healthy males and non-pregnant, non-lactating females, general population.

   Additional Comments: See above.

**Analytes to measure (in appropriate biological fluid):** Trospium in plasma.

**Bioequivalence based on (90% CI):** Trospium

**Waiver request of in-vivo testing:** Not applicable.

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods website, available to the public at the following location: [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/).
Conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application (ANDA).

In addition to the method above, for modified release products, dissolution profiles on 12 dosage units of test and reference products generated using USP Apparatus I at 100 rpm and/or Apparatus II at 50 rpm in at least three dissolution media (pH 1.2, 4.5 and 6.8 buffer) should be submitted in the application. Agitation speeds may have to be increased if appropriate. It is acceptable to add a small amount of surfactant, if necessary. Include early sampling times of 1, 2, and 4 hours and continue every 2 hours until at least 80% of the drug is released, to provide assurance against premature release of drug (dose dumping) from the formulation.

Due to a concern of dose dumping of drug from this drug product when taken with alcohol, the Agency currently requests that additional dissolution testing be conducted using various concentrations of ethanol in the dissolution medium, as follows:

Testing Conditions: 900 mL, 0.1 N HCl, USP apparatus 2 (paddle) @50 rpm, with or without alcohol;

Test 1: 12 units tested according to the proposed method (with 0.1N HCl), with data collected every 15 minutes for a total of 2 hours

Test 2: 12 units analyzed by substituting 5% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Test 3: 12 units analyzed by substituting 20% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Test 4: 12 units analyzed by substituting 40% (v/v) of test medium with Alcohol USP and data collection every 15 minutes for a total of 2 hours

Both test and RLD products must be tested accordingly and data must be provided on individual unit, means, range and %CV on both strengths.